|
1.
|
|
|
2.
|
|
19 p, 1.1 MB |
Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review
/
de Diego-Adeliño, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Crespo, José Manuel (Complejo Hospitalario Universitario de Ferrol) ;
Mora, Fernando (Hospital Universitario Infanta Leonor) ;
Neyra, Adrián (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Iborra, Pedro (Hospital Universitario San Juan de Alicante) ;
Gutiérrez-Rojas, Luis (Hospital Universitario San Cecilio (Granada)) ;
Salonia, Selman F. (Centro de Salud Mental de Jumilla) ;
Universitat Autònoma de Barcelona
Introduction: Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. [...]
2022 -  10.1080/14740338.2022.2019705
Expert Opinion on Drug Safety, Vol. 21 Núm. 5 (2022) , p. 673-690
|
|
|
3.
|
|
|
4.
|
|
15 p, 3.3 MB |
Methuosis Contributes to Jaspine-B-Induced Cell Death
/
Bielsa, Núria (Institut de Química Avançada de Catalunya) ;
Casasampere, Mireia (Institut de Química Avançada de Catalunya) ;
Abad, José Luis (Institut de Química Avançada de Catalunya) ;
Enrich, Carlos (Universitat de Barcelona. Departament de Biomedicina) ;
Delgado, Antonio (Institut de Química Avançada de Catalunya) ;
Fabriàs, Gemma (Institut de Química Avançada de Catalunya) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Casas, Josefina (Institut de Química Avançada de Catalunya)
Methuosis is a type of programmed cell death in which the cytoplasm is occupied by fluid-filled vacuoles that originate from macropinosomes (cytoplasmic vacuolation). A few molecules have been reported to behave as methuosis inducers in cancer cell lines. [...]
2022 - 10.3390/ijms23137257
International journal of molecular sciences, Vol. 23 Núm. 13 (2022) , p. 7257
|
|
|
5.
|
|
15 p, 310.8 KB |
Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts : Protocol for a Longitudinal Study Using a New Internet-Based Methodology
/
Grifell, Marc (Parc de Salut MAR de Barcelona) ;
Mir Fuster, Guillem (Asociació Benestar i Desenvolupament. Energy Control) ;
Ventura, Mireia (Asociació Benestar i Desenvolupament. Energy Control) ;
Galindo, Liliana (University of Cambridge. Department of Psychiatry) ;
Carbón Mallol, Xoán (Asociació Benestar i Desenvolupament. Energy Control) ;
Hart, Carl L.. (Columbia University. New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons. Division on Substance Abuse) ;
Pérez Solà, Víctor (Centro de Investigación Biomédica en Red de Salud Mental) ;
Colom, Francesc (Universitat Autònoma de Barcelona. Departament de Psicologia Bàsica, Evolutiva i de l'Educació)
During the last few years, the continuous emergence of new psychoactive substances (NPS) has become an important public health challenge. The use of NPS has been rising in two different ways: buying and consuming NPS knowingly and the presence of NPS in traditional drugs as adulterants. [...]
2021 - 10.2196/24433
JMIR Research Protocols, Vol. 10 (july 2021)
|
|
|
6.
|
|
|
7.
|
|
13 p, 423.1 KB |
Off-label use of rituximab in patients with different types of nephropathies in a tertiary hospital : a retrospective study
/
Sans-Pola, Carla (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Agustí Escasany, M. Antònia (Maria Antònia) (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bosch Gil, Josep Àngel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Danés Carreras, Immaculada (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Alerany, Carmen (Hospital Universitari Vall d'Hebron) ;
Agraz Pamplona, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Off-label use of rituximab is commonly requested for patients with resistant nephropathies. The outcomes and tolerability of rituximab in adult patients with nephropathy treated at our hospital (from 2013 to 2018) were described. [...]
2021 - 10.3390/jcm10214941
Journal of clinical medicine, Vol. 10 Núm. 21 (november 2021) , p. 4941
|
|
|
8.
|
|
28 p, 2.4 MB |
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
/
Di Giovanni, Giuseppe (University of Malta) ;
Svob Strac, Dubravka (Rudjer Boskovic Institute) ;
Sole, Montse (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Unzeta, Mercedes (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Tipton, Keith F. (Trinity College Dublin) ;
Mück-Šeler, Dorotea (Rudjer Boskovic Institute Zagreb, Croatia) ;
Bolea Tomás, Irene (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Della Corte, Laura (University of Florence) ;
Nikolac Perkovic, Matea (Rudjer Boskovic Institute Zagreb, Croatia) ;
Pivac, Nela (Rudjer Boskovic Institute Zagreb, Croatia) ;
Smolders, Ilse J. (Vrije Universiteit Brussels, Belgium) ;
Stasiak, Anna (Medical University of Lodz, Poland) ;
Fogel, Wieslawa A. (Medical University of Lodz, Poland) ;
De Deurwaerdère, Philippe (Institut of Neurodegenerative Diseases Bordeaux Cedex, France)
The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions. In most cases, advances have occurred through serendipity, except for Parkinson's disease where the pathophysiology led almost immediately to the introduction of dopamine restoring agents. [...]
2016 - 10.3389/fnins.2016.00541
Frontiers in Neuroscience, Vol. 10 (november 2016)
|
|
|
9.
|
|
13 p, 8.1 MB |
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans
/
Maqueda, Ana Elda (Institut d'Investigació Biomèdica Sant Pau) ;
Valle, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Addy, Peter H. (VA Connecticut Healthcare System, West Haven, CT) ;
Antonijoan Arbós, Rosa Ma. (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Puntes, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ;
Coimbra, Jimena (Institut d'Investigació Biomèdica Sant Pau) ;
Ballester, Maria Rosa ;
Garrido, Maite (Institut d'Investigació Biomèdica Sant Pau) ;
González, Mireia (Institut d'Investigació Biomèdica Sant Pau) ;
Claramunt, Judit (Institut d'Investigació Biomèdica Sant Pau) ;
Barker, Steven (kip Bertman Drive at River Road, Baton Rouge, LA) ;
Lomnicka, Izabela (kip Bertman Drive at River Road, Baton Rouge, LA) ;
Waguespack, Marian (kip Bertman Drive at River Road, Baton Rouge, LA) ;
Johnson, Matthew W. (Johns Hopkins University) ;
Griffiths, Roland R. (Johns Hopkins University) ;
Riba, Jordi (Institut d'Investigació Biomèdica Sant Pau)
Salvinorin-A is a terpene found in the leaves of the plant Salvia divinorum. When administered to humans, salvinorin-A induces an intense but short-lasting modified state of awareness, sharing features with those induced by the classical serotonin-2A receptor agonist psychedelics. [...]
2016 - 10.1093/ijnp/pyw016
International journal of neuropsychopharmacology, Vol. 19 (february 2016)
|
|
|
10.
|
|
16 p, 1.2 MB |
A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation
/
Castroviejo-Bermejo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Cruz Zambrano, Cristina (Universitat Autònoma de Barcelona) ;
Llop-Guevara, Alba (Vall d'Hebron Institut d'Oncologia) ;
Gutiérrez-Enríquez, Sara (Vall d'Hebron Institut d'Oncologia) ;
Ducy, Mandy (CHUL. Genomics Center) ;
Ibrahim, Yasir Hussein (Vall d'Hebron Institut d'Oncologia) ;
Gris-Oliver, Albert (Vall d'Hebron Institut d'Oncologia) ;
Pellegrino, Benedetta (University Hospital of Parma) ;
Bruna, Alejandra (University of Cambridge) ;
Guzmán, Marta (Vall d'Hebron Institut d'Oncologia) ;
Rodríguez, Olga (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Bonache, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Moles-Fernández, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Gómez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vidal, Marc (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Instituto de Salud Carlos III) ;
Serres-Créixams, Xavier (Hospital Universitari Vall d'Hebron) ;
Dellaire, Graham (Dalhousie University) ;
Simard, Jacques (CHUL. Genomics Center) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Hospital Universitari Vall d'Hebron) ;
Dientsmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Barrett, J. Carl (AstraZeneca) ;
Caldas, Carlos (Cancer Research UK (CRUK) Cambridge Cancer Centre) ;
Baselga Torres, Josep 1959-2021 (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Déas, Olivier (XenTech) ;
Jonkers, Jos (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Masson, Jean-Yves (Laval University Cancer Research Center) ;
Cairo, Stefano (XenTech) ;
Judde, Jean-Gabriel (XenTech) ;
O'Connor, Mark J.. (AstraZeneca) ;
Diez, Orland (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. [...]
2018 - 10.15252/emmm.201809172
EMBO Molecular Medicine, Vol. 10 (october 2018)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
